FDA Approves Apellis' Empaveli (Pegcetacoplan) As The First C3g And Primary IC-Mpgn Treatment For Patients 12 And Older
ReutersJul 28, 2025 11:21 PM
July 28 (Reuters) - Apellis Pharmaceuticals Inc APLS.O:
FDA APPROVES APELLIS’ EMPAVELI® (PEGCETACOPLAN) AS THE FIRST C3G AND PRIMARY IC-MPGN TREATMENT FOR PATIENTS 12 AND OLDER
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What to Expect From Meta Q2 Earnings: AI Push, Ad Strength — But Can Profitability Hold?
TradingKey - Meta Platforms (META), the parent company of Facebook, Instagram, and WhatsApp, will release its Q2 2025 earnings after the U.S. market close on Wednesday, July 30. After nine consecutive quarters of beating expectations, analysts expect another strong performance — driven by AI-poweredTradingKey
5 hours ago
Meta 2Q25 Earnings Preview
Meta currently trades at just 27x PE as its current state of ad business is solid. However, investors want to see whether the large spending on both infrastructure and talent actually moves the needle for the AI initiatives.TradingKey
9 hours ago
Apple Q3 FY2025 Earnings Preview: Navigating Tariff Pressures, iPhone Resilience, and AI Integration
TradingKey - Apple Inc. (NASDAQ: AAPL) is set to report its Q3 FY2025 earnings on Thursday, July 31, 2025, after the U.S. market closes. The earnings call, featuring CEO Tim Cook and CFO Kevan Parekh, will commence at 2:00 p.m. Eastern Time, providing shareholders and analysts with updates on overalTradingKey
14 hours ago
Stablecoins: Overview and Their Influence on U.S. Equity and Treasury Markets
TradingKey - The U.S. government endorses stablecoins with three primary goals. First, to reinforce the dollar's dominance: as most stablecoins are tied to the dollar, they significantly bolster its global standing.TradingKey
15 hours ago
Tradingkey
